Study guide
14.3 Panel Problem-Solving and Common Traps
Scientist in Blood Banking, BB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB
2 Donors and Collection
2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations
3 Processing, Storage, and Component QC
3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control
4 Blood Components
4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors
5 Blood Group Genetics and Transfusion Role
5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence
6 ABO and Lewis Systems
6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System
7 Rh System
7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance
8 Kell, Duffy, Kidd, and MNS
8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System
9 Additional Systems and Antigens
9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens
10 Immunology Foundations
10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties
11 Physiology, Hemostasis, Cytopenias, and Transplantation
11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation
12 Hemolytic Disease of the Fetus and Newborn
12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention
13 Routine Serologic Testing
13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing
14 Antibody Identification
14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps
15 Reagents and Special Techniques
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods
16 Serologic QA and Special Reagents
16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence
17 Indications and Component Therapy
17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy
18 Adverse Effects of Transfusion
18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases
19 Apheresis, Administration, and Patient Blood Management
19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management
20 Laboratory Operations
20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation
14.3 Panel Problem-Solving and Common Traps
Key Takeaways Explain This Topic AI
Passive anti-D from RhIG is usually weak, low-titer, and history-dated — finish the other rule-outs and do not call the patient immunized.
Rouleaux disperses with saline replacement and vanishes after washing; true agglutination does not.
Cold auto, drugs, recent-transfusion mixed field, and a positive DAT are the four ways a phenotype or panel lies; prewarm/adsorb, get a drug list, genotype, or strip IgG.
Neutralize Lewis, P1, Ch/Rg, and Sda; DTT-treated cells destroy Kell, Lutheran, Dombrock, and JMH, while DTT-treated serum destroys IgM.
Screen positive, AC positive, panel all positive is warm auto versus high-prevalence versus multiple allo — DAT, history, and adsorption decide, and unresolved cases go to the IRL.
Last updated: August 2026
14.3 Panel Problem-Solving and Common Traps
Quick Answer: Before you name an antibody, exclude the look-alikes : RhIG anti-D , HTLA , rouleaux (saline replacement), cold auto masking allo (prewarm or cold adsorption), drug antibodies, recent-transfusion mixed field , and a positive DAT that invalidates phenotyping. Neutralize Lewis, P1, Ch/Rg, and Sda. A DTT-treated cell panel destroys Kell, Lutheran, Dombrock, JMH (and some others); DTT-treated serum knocks out IgM . Screen pos / AC pos / panel all pos is warm auto versus high-prevalence versus multiple antibodies — DAT, history, and adsorption decide. Send unresolved high-prevalence, hidden allo, and rare-unit problems to the IRL .
The clean anti-Jka panel in Section 14.1 is the teaching case. The exam also writes the dirty ones. IV.A.3 expects you to name the trap and the next tube, not to force a single specificity onto a panagglutinin.
Passive anti-D is not immunization
A D-negative woman at 28 weeks or postpartum, or after a massive-FMH dose of RhIG , will have anti-D on the panel. It is passive , usually ≤1+ to 2+ , titer often ≤4 , AC negative, and the history dates the injection. Do not call her immunized, do not stop future RhIG, and do not hunt a second antibody so hard that you forget to finish non-D rule-outs — RhIG does not explain anti-K or anti-Jka. If the titer is high (classically ≥16 ) or the last RhIG was months ago , treat it as immune anti-D until proven otherwise.
HTLA versus a real alloantibody
High-titer, low-avidity (HTLA) antibodies (Knops, Ch/Rg, Yka, Csa) give weak (weak 1+ to 1+) reactions with most or all panel cells, little dosage, and a negative or weak AC . The giveaway is that the weak reaction survives dilution — a titer of 64 with a 1+ endpoint. They do not cause HTR. Anti-Ch and anti-Rg are neutralized by pooled plasma (soluble C4). Knops antibodies are weakened by DTT or enzymes . Do not spend a night of selected cells on a 1+ panagglutinin that titers to 128 and is neutralized by plasma — but do make sure a clinically significant antibody is not hiding underneath (PEG, selected cells, or adsorption). HTLA is a diagnosis of a named system after you have excluded Kidd, Duffy, Rh, Kell, and S/s, not a shrug that skips rule-out.
Rouleaux is not agglutination
Rouleaux (stacked-coin red cells) happens in paraprotein , Wharton's jelly , and some high-protein enhancement media. It appears at IS and 37 °C and disappears after washing , so the AHG phase is usually negative . True IgG agglutination survives wash and is read at AHG. Saline replacement : centrifuge the plasma-cell mix, remove plasma, replace with saline, resuspend. Rouleaux disperses; true agglutination does not. Do not “rule in anti-M” on an IS-only panel that clears with saline replacement, and do not call rouleaux a warm auto — the AC at AHG after washing should be 0.
Cold auto masking allo, drugs, mixed field, and a DAT that lies about the phenotype
Cold autoanti-I (or IH) reacts with all adult cells including the AC at IS/RT and can carry into 37 °C if you do not warm things properly. It can mask an IgG alloantibody . Fix: prewarm technique (cells, plasma, and saline at 37 °C, no IS read) or cold autologous adsorption , then run a strict 37 °C / AHG panel. Cord cells (i) are a clue, not a full workup. Do not prewarm so aggressively that you melt a Kidd antibody — prewarm is for cold panagglutination, not for a clean AHG screen you simply dislike.
Drug-dependent antibodies (piperacillin, cefotetan, penicillin) produce a positive DAT . The eluate may be nonreactive with untreated cells and reactive only in the presence of drug . Methyldopa / fludarabine-type autoantibodies behave like warm autos. Get a medication list before you call every panagglutinin idiopathic WAIHA.
Recent transfusion produces mixed-field antigen typing and can make the AC and DAT positive because alloantibody is coating donor cells (delayed serologic or hemolytic reaction). Phenotype is invalid . Use genotype or retic separation . The “panel” may be the patient's new alloantibody plus leftover donor cells in the AC.
A positive DAT invalidates antigen typing that uses AHG or high-protein reagents — the cells are already coated. Use monoclonal IgM direct agglutinins, or strip IgG with chloroquine diphosphate or EGA and repeat. Do not report a patient as e+ on an AHG anti-e when the DAT is 3+.
Neutralization and the DTT panel
Soluble substance neutralizes some antibodies so leftover reactivity can be identified:
- Antibody Neutralizing substance Teaching tell
- Lewis Saliva (secretor / Lewis-positive) or commercial Lewis substance Usually IS/RT; not on cord cells
- P1 Hydatid cyst fluid, pigeon egg white, P1 substance Cold, often insignificant
- Ch/Rg Pooled plasma (C4) Weak AHG panagglutinin, high titer
- Sda Urine (Tamm–Horsfall / Sd(a) substance) Refractile mixed-field agglutinates
If neutralization kills the reactions, that was the antibody. If reactions remain , something significant is underneath.
DTT-treated reagent cells lose antigens that depend on disulfide bonds: Kell, Lutheran, Dombrock, JMH, Yt, Knops, LW (weakened), and CD38 (daratumumab interference). Rh, Kidd, Duffy, and MNS survive. An unidentified AHG antibody that vanishes on DTT cells is in a DTT-sensitive system — most often Kell . DTT-treated plasma/serum disrupts IgM pentamers. Reactivity that disappears after treating the serum (not the cells) is IgM , not IgG anti-K. That is how you separate IgM noise from true IgG anti-K , and how you strip IgM so you can see IgG underneath.
Daratumumab (anti-CD38) makes a panagglutinin at AHG. DTT-treated panel cells (CD38 destroyed) let you rule out most alloantibodies, but Kell is also destroyed , so you cannot rule out anti-K on a DTT panel — issue K− units or use a non-DTT method for K.
Worked scenario: screen positive, autocontrol positive, panel all positive
A 68-year-old with anemia: screen 3+ all cells , AC 3+ , 11-cell panel 3+ with every cell at AHG , IS negative.
- Observation Warm auto High-prevalence allo Multiple allo + recent transfusion
- Autocontrol Positive Negative (pure) Positive if donor cells are still circulating
DAT / eluate IgG+, eluate panreactive DAT often neg ; eluate neg or not indicated DAT pos (often mixed-field); eluate may match donor antigens
Patient type Common phenotype Missing a high-prevalence antigen (U, k, Vel) Missing several common antigens
History AIHA, CLL, fludarabine, methyldopa Untransfused or remote transfusion Transfusion days to weeks ago, falling Hb
Next tube Autoadsorb if not recently transfused; differential adsorb if transfused Rare cell, enzymes/DTT, IRL Differential adsorption + genotype
This single picture has three exam diagnoses. You do not pick one from the panel alone.
1. Warm autoantibody. DAT IgG-positive , eluate panreactive , no recent transfusion. The panel is the auto. Next question: is there an underlying alloantibody ? If not recently transfused → autologous adsorption , then panel the adsorbed plasma. If recently transfused → differential allogeneic adsorption . Do not just issue “least incompatible” without looking for alloanti-Jka underneath.
2. High-prevalence alloantibody with a coincidentally positive AC (or high-prevalence plus a warm auto). Clue: the patient types negative for a high-prevalence antigen (U, k, Kpb, Vel, Lub). The AC should be negative for a pure high-prevalence allo — if AC is truly 3+ with a negative DAT, suspect a technique problem. A negative AC with a panreactive panel is the cleaner high-prevalence postcard (Section 14.2).
3. Multiple alloantibodies covering every panel cell, plus a positive AC from recent transfusion . Clue: transfusion 10 days ago , falling hemoglobin, mixed-field DAT or phenotype, eluate reactive with some cells (the donor phenotype) rather than all. Selected cells and phenotype-matched adsorbing cells unravel the mixture.
Algorithm: history (transfusion, pregnancy, RhIG, daratumumab, antibiotics) → DAT IgG/C3 → eluate → phenotype or genotype → enzymes/DTT/neutralization as indicated → adsorption if auto → IRL if you still have a panagglutinin you cannot name or you need rare antigen-negative units .
When to send to the IRL
Send, do not guess:
Suspected high-prevalence antibody or antibody to an unidentified specificity after selected cells.
Warm auto in a recently transfused patient when you cannot complete differential adsorption.
Need for rare units (Ko, U−, Vel−, PP1Pk−, Jk(a−b−)).
HDFN with a rare maternal antibody.
Discrepant neutralization / DTT / enzyme results.
HTLA versus clinically significant that you cannot separate.
Ship plasma, EDTA cells, and a DAT/eluate if already done. Tell them the transfusion and drug history . The IRL is not a substitute for finishing the homozygous rule-outs you can do locally.
Exam traps
Calling RhIG anti-D immune and withholding later RhIG.
Antigen-negative units for a Knops antibody.
Reading rouleaux at IS as anti-M and skipping saline replacement.
Prewarming away a Kidd antibody because you were chasing a cold.
Phenotyping through a 3+ DAT .
Using a DTT cell panel to rule out anti-K in a daratumumab patient — DTT destroys K .
Issuing least-incompatible blood for a panagglutinin without adsorption .